Financial Results Overview
Standalone Financial Results (in lakhs):
- Q4 FY26 Revenue from operations: ₹5.45 lakhs (compared to ₹7.65 lakhs in Q4 FY25)
- Q4 FY26 Other income: ₹14.99 lakhs (compared to ₹4.38 lakhs in Q4 FY25)
- Q4 FY26 Total income: ₹20.43 lakhs (compared to ₹12.03 lakhs in Q4 FY25)
- Q4 FY26 Total expenses: ₹66.13 lakhs (including finance costs of ₹27.68 lakhs and depreciation of ₹4.98 lakhs)
- Q4 FY26 Net loss: ₹45.70 lakhs (compared to ₹71.31 lakhs loss in Q4 FY25)
- FY26 Net loss: ₹165.29 lakhs (compared to ₹67.61 lakhs loss in FY25)
- Basic and diluted EPS: (₹0.06) per share for Q4 FY26, (₹0.22) per share for FY26
Consolidated Financial Results (in lakhs):
- Results are identical to standalone results as the subsidiary Transgene Biotek HK Ltd has been non-operational since 2015-16 with no transactions
Key Financial Metrics
Balance Sheet (Standalone as of March 31, 2026):
- Total assets: ₹3376.47 lakhs
- Equity share capital: ₹7577.00 lakhs
- Other equity: negative ₹8496.98 lakhs
- Total borrowings: ₹1713.68 lakhs (₹680.08 lakhs non-current + ₹1033.60 lakhs current)
- Provisions: ₹2435.25 lakhs (₹2302.04 lakhs non-current + ₹133.21 lakhs current)
- Cash and cash equivalents: ₹6.07 lakhs
Cash Flow (Standalone FY26):
- Net cash from operating activities: negative ₹1.13 lakhs
- Net cash from investing activities: ₹15.00 lakhs (from sale of fixed assets/shares)
- Net cash from financing activities: negative ₹36.23 lakhs
- Net decrease in cash: ₹22.36 lakhs
Audit Details
The company received an unmodified audit opinion from M/s. Vasavi & Co, Chartered Accountants (FRN 020965S, MRN 249259) for both standalone and consolidated financial results. The audit report was dated May 29, 2026, and signed by CA Vasavi Gollapudi, Proprietor.
Legal and Regulatory Proceedings
1. Securities Appellate Tribunal (SAT): Appeal against SEBI was listed for hearing on April 1, 2026, and adjourned to July 14, 2026.
2. Appellate Tribunal (ED), New Delhi: Appeal against ED Adjudication Officer's order was heard on April 13, 2026, and posted for further hearing on July 23, 2026.
3. SBIRI/BIRAC: No further communication since last board meeting on November 14, 2025.
4. Customs & Excise Department: No further developments since last board meeting.
5. NCLT: Matter came up for hearing on April 13, 2026, and adjourned to July 8, 2026.
6. Complaints: Zero complaints pending at beginning of quarter; zero complaints received during quarter.
Other Matters
The subsidiary Transgene Biotek HK Ltd has not been in operations, and its books of accounts have not been audited for many years. The company is not recognizing foreign gain or loss as there have been no transactions since many years. The last available figures are from 2015-16 and are being carried forward for consolidation.
Additional Information
- The company has 757.70 lakh equity shares of ₹10 each outstanding
- Other expenses for Q4 FY26 included Legal and Professional Charges of ₹23.78 lakhs (standalone) and ₹8.78 lakhs (consolidated)
- The financial results include balancing figures between audited full-year figures and previously published unaudited figures